Stock Track | SBP GROUP Soars 5.19% Intraday on AstraZeneca and GSK Licensing Deals

Stock Track07-09

SBP GROUP's stock price surged 5.19% during intraday trading on Thursday, following the announcement of significant new licensing agreements.

The company has entered into a major licensing deal with AstraZeneca for its self-developed PDE3/4 inhibitor, TQC3721. Under the agreement, AstraZeneca will pay an upfront fee of US$200 million and could pay up to US$1.7 billion in milestone payments, plus tiered royalties. This marks SBP GROUP's second major licensing agreement with a multinational pharmaceutical corporation this year, demonstrating strong recognition of its internal R&D and innovation capabilities.

Simultaneously, SBP GROUP has deepened its strategic partnership with GSK, securing the commercialization rights for two of GSK's major respiratory drugs in mainland China. This dual partnership development, covering both significant upfront payments and expanded commercial opportunities, has provided substantial positive sentiment for the company's growth prospects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1170050464?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-09 10:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170050464","market":"us","top_or_hot":-1,"title":"Stock Track | SBP GROUP Soars 5.19% Intraday on AstraZeneca and GSK Licensing Deals","media":"Stock Track","content":"<p>SBP GROUP's stock price surged 5.19% during intraday trading on Thursday, following the announcement of significant new licensing agreements.</p><p>The company has entered into a major licensing deal with AstraZeneca for its self-developed PDE3/4 inhibitor, TQC3721. Under the agreement, AstraZeneca will pay an upfront fee of US$200 million and could pay up to US$1.7 billion in milestone payments, plus tiered royalties. This marks SBP GROUP's second major licensing agreement with a multinational pharmaceutical corporation this year, demonstrating strong recognition of its internal R&D and innovation capabilities.</p><p>Simultaneously, SBP GROUP has deepened its strategic partnership with GSK, securing the commercialization rights for two of GSK's major respiratory drugs in mainland China. This dual partnership development, covering both significant upfront payments and expanded commercial opportunities, has provided substantial positive sentiment for the company's growth prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | SBP GROUP Soars 5.19% Intraday on AstraZeneca and GSK Licensing Deals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | SBP GROUP Soars 5.19% Intraday on AstraZeneca and GSK Licensing Deals\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-07-09 10:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SBP GROUP's stock price surged 5.19% during intraday trading on Thursday, following the announcement of significant new licensing agreements.</p><p>The company has entered into a major licensing deal with AstraZeneca for its self-developed PDE3/4 inhibitor, TQC3721. Under the agreement, AstraZeneca will pay an upfront fee of US$200 million and could pay up to US$1.7 billion in milestone payments, plus tiered royalties. This marks SBP GROUP's second major licensing agreement with a multinational pharmaceutical corporation this year, demonstrating strong recognition of its internal R&D and innovation capabilities.</p><p>Simultaneously, SBP GROUP has deepened its strategic partnership with GSK, securing the commercialization rights for two of GSK's major respiratory drugs in mainland China. This dual partnership development, covering both significant upfront payments and expanded commercial opportunities, has provided substantial positive sentiment for the company's growth prospects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01177","symbol_name":"中国生物制药","start_time":0,"source_url":"","article_id":"1170050464","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170050464","pubTimestamp":1783562601,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"SBP GROUP's stock price surged 5.19% during intraday trading on Thursday, following the announcement of significant new licensing agreements.The company has entered into a major licensing deal with...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01177":"中国生物制药"},"translate_title":"个股追踪|阿斯利康和GSK授权交易推动SBP集团盘中大涨5.19%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":1},"content_text":"SBP GROUP's stock price surged 5.19% during intraday trading on Thursday, following the announcement of significant new licensing agreements.The company has entered into a major licensing deal with AstraZeneca for its self-developed PDE3/4 inhibitor, TQC3721. Under the agreement, AstraZeneca will pay an upfront fee of US$200 million and could pay up to US$1.7 billion in milestone payments, plus tiered royalties. This marks SBP GROUP's second major licensing agreement with a multinational pharmaceutical corporation this year, demonstrating strong recognition of its internal R&D and innovation capabilities.Simultaneously, SBP GROUP has deepened its strategic partnership with GSK, securing the commercialization rights for two of GSK's major respiratory drugs in mainland China. This dual partnership development, covering both significant upfront payments and expanded commercial opportunities, has provided substantial positive sentiment for the company's growth prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1170050464","isCrawlerRequest":true}